ABM Respiratory Care (ABMRC), a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, announced the closing of its Series B financing round, raising $14.8 million—well above its $12 million target. This oversubscribed round was led by Peter Soderberg, ABMRC’s Chairman of the Board and Managing Partner of Worthy Venture Resources, who more than doubled his investment in the company.
This funding round also included significant participation from Bluwave Capital, with one of the co-founding Partners joining the Board of Directors, along with other new and existing investors committed to advancing innovation in respiratory care.
BiWaze Clear helps people clear their lungs more efficiently by combining three therapies in one: lung expansion, high-frequency oscillations, and aerosol delivery with an integrated nebulizer. And its compact, battery-operated design and dual-lumen circuit create a portable, closed-loop system that enhances aerosol deposition deep in the lungs, improves mucus clearance, and shortens therapy time, making it easier for patients to use at home or in the hospital.
How the funding will be used: The funding will be used to accelerate the commercialization of BiWaze Clear, ABM Respiratory Care’s latest airway clearance system, designed for both hospital and home use. And this includes scaling U.S. sales efforts, investing in clinical research, and enhancing patient engagement and digital health capabilities.
KEY QUOTES:
“This investment marks a pivotal moment for ABM Respiratory Care as we expand access to our respiratory therapy platform and bring transformative solutions into more homes and hospitals. We’re grateful for the support of our new and existing investors who are excited about our vision for intelligent, connected therapies of people struggling to breathe.”
Greg Miller, CEO of ABMRC
“I was motivated to increase my ownership of ABMRC given its impressive execution to-date and the superior performance of its first two devices in treating patients across the continuum of care. We welcome the opportunity to support the company’s next phase of growth as it expands access to our impactful technology to patients worldwide.”
Peter Soderberg
